Tirofiban

Research use only, not for human use.

A potent, selective inhibitor of the platelet fibrinogen receptor GPIIb/IIIa with IC50 of 9 nM.

A potent, selective inhibitor of the platelet fibrinogen receptor GPIIb/IIIa with IC50 of 9 nM, inhibition of platelet aggregation; displays > 24,000-fold over human umbilical vein endothelial cell fibrinogen receptors; inhibits ex vivo platelet aggregation induced by ADP in anesthetized dogs.Thrombosis Approved.

Cell Proliferation AssayCell Line:HAEC cells Concentration:0.25, 1, 3 μg/mL Incubation Time:72 hours Result:Increased proliferation of HAEC cells.Cell Migration Assay Cell Line:HUVEC cells Concentration:Incubation Time:24 hours Result:Stimulated the migratory capacity of endothelial cells.Western Blot Analysis Cell Line:HAEC cells Concentration:0.05, 0.12, 0.25, 1 μg/mL Incubation Time:1 hour Result:Induced production of VEGF which stimulated proliferation of endothelial cells.

Animal Model:Male Sprague-Dawley rats (10 to 15-week-age; 270-330 g).Dosage:60 μg/kg Administration:Intravenous injection; once.Result:Increased contraction force, ventricular compliance, and improved heart function.Reduced the size of no-reflow and infarct.Animal Model:Sprague-Dawley rats (350-400 g; crush injury model)Dosage:50 μg/per (50 μg/mL, 1 mL for each) Administration:Irrigate 1 mL within the vessel lumen (before placement of the last suture); once.Result:Showed anticoagulant effect with patency rates of 59%.

L-700462 | MK-383 | MK-0383

Cell Cycle/DNA Damage

Integrin

GPIIb/IIIa

Cardiovascular Disease

Thrombosis

144494-65-5

440.5966

C22H36N2O5S

>98% (HPLC)

DMSO: < 1 mg/mL

O=C(O)[C@H](CC1=CC=C(OCCCCC2CCNCC2)C=C1)NS(=O)(CCCC)=O

L-Tyrosine, N-(butylsulfonyl)-O-[4-(4-piperidinyl)butyl]-

(-20℃)

With Ice Pack

≥ 2 years